The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Development of the Proteasome Inhibitor Velcade™ (Bortezomib)
Abstract
The dipeptide boronic acid analogue VELCADE (Bortezomib; formerly known as PS-341, LDP-341 and MLM341) is a potent and selective inhibitor of the proteasome, a multicatalytic enzyme that mediates many cellular regulatory signals by degrading regulatory proteins or their inhibitors. The proteasome is, thus, a potential target for pharmacological agents. Bortezomib, the first proteasome inhibitor to reach clinical trials, has shown in vitro and in vivo activity against a variety of malignancies, including myeloma, chronic lymphocytic leukemia, prostate cancer, pancreatic cancer, and colon cancer. The drug is rapidly cleared from the vascular compartment, but a novel pharmacodynamic assay has shown that bortezomib--mediated proteasome blockade is dose-dependent and reversible. Based on phase I studies demonstrating that bortezomib has manageable toxicities in patients with advanced cancers, phase II trials have been initiated for both solid and hematological malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, C.-Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., & Baldwin, A. S. (1998) · Science · doi:10.1126/science.281.5383.1680 · Cited by 2,711
Structure of 20S proteasome from yeast at 2.4Å resolution
Groll, M., Ditzel, L., Löwe, J., Stock, D., Bochtler, M., Bartunik, H. D., & Huber, R. (1997) · Nature · doi:10.1038/386463a0 · Cited by 2,257
Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F., & Rolfe, M. (1995) · Science · doi:10.1126/science.7624798 · Cited by 1,817
Crystal Structure of the 20 S Proteasome from the Archaeon T. acidophilum at 3.4 Å Resolution
Löwe, J., Stock, D., Jap, B., Zwickl, P., Baumeister, W., & Huber, R. (1995) · Science · doi:10.1126/science.7725097 · Cited by 1,525
Hideshima, T., Richardson, P. G. G., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., & Anderson, K. C. (2001) · PubMed · Cited by 1,508
Self-citationProteasome inhibitors: a novel class of potent and effective antitumor agents.
Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J. I., Destree, A. T., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., & Elliott, P. J. (1999) · PubMed · Cited by 1,477
Self-citationDulić, V., Kaufmann, W. K., Wilson, S. J., Tisty, T. D., Lees, E., Harper, J. W., Elledge, S. J., & Reed, S. I. (1994) · Cell · doi:10.1016/0092-8674(94)90379-4 · Cited by 1,465
Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
Baldwin, A. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11991 · Cited by 1,434
Chen, Z., Hagler, J., Palombella, V. J., Melandri, F., Scherer, D., Ballard, D., & Maniatis, T. (1995) · Genes & Development · doi:10.1101/gad.9.13.1586 · Cited by 1,290
How Proteolysis Drives the Cell Cycle
King, R. W., Deshaies, R. J., Peters, J.-M., & Kirschner, M. W. (1996) · Science · doi:10.1126/science.274.5293.1652 · Cited by 1,273
Winston, J. T., Strack, P., Beer-Romero, P., Chu, C. Y., Elledge, S. J., & Harper, J. W. (1999) · Genes & Development · doi:10.1101/gad.13.3.270 · Cited by 954
The Rel/NF-κB Family Directly Activates Expression of the Apoptosis Inhibitor Bcl-x L
Chen, C., Edelstein, L. C., & Gélinas, C. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.8.2687-2695.2000 · Cited by 760
Zong, W.-X., Edelstein, L. C., Chen, C., Bash, J., & Gelinas, C. (1999) · Genes & Development · doi:10.1101/gad.13.4.382 · Cited by 720
Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
Adams, J., Behnke, M., Chen, S., Cruickshank, A. A., Dick, L. R., Grenier, L., Klunder, J. M., Ma, Y.-T., Plamondon, L., & Stein, R. L. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00029-8 · Cited by 685
Self-citationWang, C.-Y., Guttridge, D. C., Mayo, M. W., & Baldwin, A. S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.5923 · Cited by 590
Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination.
Scherer, D. C., Brockman, J. A., Chen, Z., Maniatis, T., & Ballard, D. W. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.24.11259 · Cited by 554
Houston, M. A., Abendroth, K., Baldwin, A. S., & Liu, R. (2001) · PubMed · doi:10.17615/k359-fr77 · Cited by 547
Activation of the cell death program by inhibition of proteasome function
Drexler, H. C. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.3.855 · Cited by 481
Alkalay, I., Yaron, A., Hatzubai, A., Orian, A., Ciechanover, A., & Ben-Neriah, Y. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.23.10599 · Cited by 440
Signal-induced ubiquitination of Ikappa Balpha by the F-box protein Slimb/beta -TrCP
Spencer, E., Jiang, J., & Chen, Z. J. (1999) · Genes & Development · doi:10.1101/gad.13.3.284 · Cited by 431
Development of the Proteasome Inhibitor PS-341
Adams, J. (2002) · The Oncologist · doi:10.1634/theoncologist.7-1-9 · Cited by 369
Self-citationAn, B., Goldfarb, R. H., Siman, R., & Dou, Q. P. (1998) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400436 · Cited by 337
Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-κB
Russo, S. M., Tepper, J. E., Baldwin, A. S., Liu, R., Adams, J., Elliott, P., & Cusack, J. C. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01446-8 · Cited by 318
Self-citationCleavage motifs of the yeast 20S proteasome β subunits deduced from digests of enolase 1
Nussbaum, A. K., Dick, T. P., Keilholz, W., Schirle, M., Stevanović, S., Dietz, K., Heinemeyer, W., Groll, M., Wolf, D. H., Huber, R., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.21.12504 · Cited by 311
Proteasome Inhibition Measurements: Clinical Application
Lightcap, E. S., McCormack, T. A., Pien, C. S., Chau, V., Adams, J., & Elliott, P. J. (2000) · Clinical Chemistry · doi:10.1093/clinchem/46.5.673 · Cited by 301
Self-citationPatel, N. M., Nozaki, S., Shortle, N. H., Bhat-Nakshatri, P., Newton, T. R., Rice, S., Gelfanov, V., Boswell, S. H., Goulet, R. J., Sledge, G. W., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203768 · Cited by 294
Ubiquitin-dependent Destruction of Topoisomerase I Is Stimulated by the Antitumor Drug Camptothecin
Desai, S. D., Liu, L. F., Vazquez-Abad, D., & D'Arpa, P. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.39.24159 · Cited by 269
Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells
Kordes, U., Krappmann, D., Heissmeyer, V, Ludwig, W., & Scheidereit, C. (2000) · Leukemia · doi:10.1038/sj.leu.2401705 · Cited by 264
26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer
Shah, S. A., Potter, M. W., McDade, T. P., Ricciardi, R., Perugini, R. A., Elliott, P. J., Adams, J., & Callery, M. P. (2001) · Journal of Cellular Biochemistry · doi:10.1002/jcb.1150 · Cited by 260
Self-citationProteasome Inhibition: a New Strategy in Cancer Treatment
Adams, J., Palombella, V. J., & Elliott, P. J. (2000) · Investigational New Drugs · doi:10.1023/a:1006321828515 · Cited by 248
Self-citationLin, Y. C., Brown, K., & Siebenlist, U. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.2.552 · Cited by 246
Inhibition of Nuclear Factor κB Activation Attenuates Apoptosis Resistance in Lymphoid Cells
Jeremias, I., Kupatt, C., Baumann, B., Herr, I., Wirth, T., & Debatin, K. M. (1998) · Blood · doi:10.1182/blood.v91.12.4624 · Cited by 230
Role of I Bα Ubiquitination in Signal-induced Activation of NF- B in Vivo
Roff, M., Thompson, J., Rodriguez, M. S., Jacque, J.-M., Baleux, F., Arenzana-Seisdedos, F., & Hay, R. T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.13.7844 · Cited by 214
Chemosensitization of Pancreatic Cancer by Inhibition of the 26S Proteasome
Bold, R. J., Virudachalam, S., & McConkey, D. J. (2001) · Journal of Surgical Research · doi:10.1006/jsre.2001.6194 · Cited by 212
Proteasome inhibition in cancer: Development of PS-341
ADAMS, J. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90034-x · Cited by 209
Self-citationAn, W., Hwang, S.-G., Trepel, J., & Blagosklonny, M. (2000) · Leukemia · doi:10.1038/sj.leu.2401812 · Cited by 207
Critical Role for Lysines 21 and 22 in Signal-induced, Ubiquitin-mediated Proteolysis of IkB-α
Baldi, L., Brown, K., Franzoso, G., & Siebenlist, U. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.1.376 · Cited by 177
Masdehors, P., Ōmura, S., Merle‐Béral, H., Mentz, F., Cosset, J., Dumont, J., Magdelénat, H., & Delić, J. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01388.x · Cited by 159
New insights into role of microenvironment in multiple myeloma
Tricot, G. J. K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)00019-2 · Cited by 149
Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs.
Ogiso, Y., Tomida, A., Lei, S., Ōmura, S., & TSURUO, T. (2000) · PubMed · Cited by 141
Dietrich, C., Bartsch, T., Schanz, F., Oesch, F., & Wieser, R. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10815 · Cited by 77
The proteasome controls the expression of a proliferation-associated nuclear antigen Ki-67
Wu, Y., Luo, H., Kanaan, N., & Wu, J. (2000) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(20000315)76:4<596::aid-jcb8>3.0.co;2-n · Cited by 42
Proteasome inhibitor PS-341 inhibits human multiple myeloma cell growth in a murine model.
LeBlanc, R., Catley, L. P., Hideshima, T., Pien, C. S., Elliott, P., & Anderson, K. C. (2001) · Blood · Cited by 14
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Inflammation meets cancer, with NF-κB as the matchmaker
Ben-Neriah, Y., & Karin, M. (2011) · Nature Immunology · doi:10.1038/ni.2060 · Cited by 1,373
Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer
Frescas, D., & Pagano, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2396 · Cited by 890
Broad targeting of resistance to apoptosis in cancer
Mohammad, R. M., Muqbil, I., Lowe, L., Yedjou, C., Hsu, H.-Y., Lin, L.-T., Siegelin, M. D., Fimognari, C., Kumar, N. B., Dou, Q. P., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.001 · Cited by 864
Ubiquitylation and cell signaling
Haglund, K., & Dikic, I. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600808 · Cited by 734
Metadata
- Authors
- Adams, J., & Kauffman, M.
- Venue
- Cancer Investigation
- Publisher
- Informa UK Limited
- Published
- 2004-01
- Volume
- 22
- Issue
- 2
- Pages
- 304-311
- ISSN
- 0735-7907 (ISSN-L)
- 1532-4192
- OpenAlex
- W2152091753
- Cited by
- 654
- References
- 43
- FWCI
- 9.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.